Inhibiting CCR3 has demonstrated efficacy in reducing Th2 immune responses for treatment of severe asthma [16,17], and our group found the Th2 immune response itself to be positively associated with increased infarct volume and edema in stroke patients undergoing thrombectomy [8]. This evidence concerns the gene CCR3 and Stroke.